Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy with Lenacapavir-Containing Regimen

Thomas Montrouge; Mélanie Bertine; Gilles Peytavin; Thibault Saint Joannis; Antoine Bachelard; Pierre De Truchis; Sylvie Lariven; Philippe Morlat; Cécile Pouderoux; Florence Damond; Naomi Sayre; Roland Tubiana; Nadia Valin; Charlotte Charpentier; Diane Descamps; Jade Ghosn; Quentin Le Hingrat

doi:10.1093/cid/ciae650

Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy with Lenacapavir-Containing Regimen

Clin Infect Dis. 2024 Dec 31:ciae650. doi: 10.1093/cid/ciae650. Online ahead of print.

Authors

Thomas Montrouge¹, Mélanie Bertine^{1

2}, Gilles Peytavin³, Thibault Saint Joannis², Antoine Bachelard⁴, Pierre De Truchis⁵, Sylvie Lariven⁴, Philippe Morlat⁶, Cécile Pouderoux⁷, Florence Damond², Naomi Sayre⁸, Roland Tubiana^{7

9}, Nadia Valin¹⁰, Charlotte Charpentier^{1

2}, Diane Descamps^{1

2}, Jade Ghosn^{1

4}, Quentin Le Hingrat^{1

2}

Affiliations

¹ Université Paris Cité, Inserm, IAME, F-75018, Paris, France.
² Service de Virologie, Centre National de Référence VIH, AP-HP, Hôpital Bichat-Claude Bernard, F-75018, Paris, France.
³ Service de Pharmacologie, AP-HP, Hôpital Bichat-Claude Bernard, F-75018, Paris, France.
⁴ Service de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Bichat-Claude Bernard, F-75018, Paris, France.
⁵ Service de Médecine Interne, AP-HP, Hôpital Raymond Poincaré, F-92380, Garches, France.
⁶ Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, F-33000, Bordeaux, France.
⁷ Service de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Pitié-Salpêtrière, F-75013, Paris, France.
⁸ Service de Maladies Infectieuses et Tropicales, Hôpital Saint Denis, F-93205, Saint Denis, France.
⁹ INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), F-75013 Paris, France.
¹⁰ Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint Antoine, F-75012, Paris, France.

PMID: 39737782
DOI: 10.1093/cid/ciae650

Abstract

Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with multi-drug resistant HIV-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug-resistance associated mutations.

Keywords: HIV-2; capsid; lenacapavir; resistance.

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.